Feasibility Study of DermGEN for Diabetic Foot Ulcer Treatment

Diabetes Type II Clinical Trial

Official title:

A Feasibility Study of DermGEN Dermal Regeneration Scaffold for the Treatment of Diabetic Foot Ulcers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02184455
• Other study ID #: DeCell-001
• Status: Completed
• Phase: Phase 1
• Start date: July 1, 2016
• Est. completion date: May 1, 2017

Study information

• Verified date: September 2019
• Source: DeCell Technologies Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this clinical trial is to perform a limited pilot study to determine the safety and feasibility of DermGEN in the treatment of non-healing diabetic foot ulcers (DFU). This will be a one-arm prospective study. It is hypothesized that DermGEN treatment will result in positive healing outcomes with no significant adverse effects.

Description:

This will be a one-arm prospective study. This study in Halifax will be mirrored in one other participating health care center in Toronto, Ontario, Canada with each centre anticipated to enrol 5-10 patients for a total of 15-20 patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 11
• Est. completion date: May 1, 2017
• Est. primary completion date: May 1, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

A subject will be considered eligible to participate in this study if each of the following inclusion criteria is satisfied:

1. Patient with documented stable Type I or II diabetes (HbA1C >7.0 within 1 month prior to Day 0).

2. Patient's ulcer has been present for a minimum of 2 weeks as of Day 0.

3. Study ulcer has healed <30% in size during the 2 weeks prior to Day 0.

4. Ulcer area is =1 cm2 prior to debridement at Day 0 of study.

5. Ulcer extends through dermis and into subcutaneous tissue but without exposure of muscle, tendon, bone or joint capsule.

6. Ulcer is free of necrotic debris and clinical infection, and is comprised of healthy vascular tissue suitable for skin grafting on Day 0.

7. Patient has adequate circulation to the foot as evidenced by palpable pulse or pulse detectable with Doppler ultrasound, and lack of visible cyanosis in skin bordering the ulcer.

8. Female patients are not pregnant at time of, or during study.

9. Patient and caregiver ready and willing to participate and comply with follow-up regime.

10. Patient or legal representative has read and signed the Institutional Ethics Review Board approved informed consent form.

Exclusion Criteria:

A subject will not be considered eligible to participate in this study if any one of the following exclusion criteria is satisfied:

1. Evidence of gangrene on affected foot.

2. Ulcer is over Charcot deformity (fractures or dislocation).

3. Ulcer is non-diabetic in etiology.

4. Ulcer has tunnels or sinus tracts that cannot be completely debrided.

5. Medical condition(s) that in the Investigator's opinion make the patient inappropriate for study

6. Patient has/had malignant disease not in remission for 5 years or more

7. Patient has acute or chronic hepatitis, cirrhosis, serum albumin <2.0 gm/dL, or has alkaline phosphatase or LDH at twice the normal upper limit

8. Patient receiving oral or parenteral corticosteroids, immunosuppression or cytotoxic agents, or is anticipated to require such agents during study

9. Patient received radiation therapy within 30 days of Day 0 of study

10. Patient has AIDS or is infected with HIV

11. Patient has participated in another study using investigational drug(s) or device within the previous 30 days

12. Obvious clinical signs and symptoms of ongoing cellulitis or osteomyelitis

13. Patient has any other condition which seriously compromises their ability to complete the study

14. Patient has known allergies to antibiotics, such as penicillin and streptomycin

15. Patient has a history of bleeding disorder

16. Patient received elective osseous procedures to the study foot within 30 days prior to screening visit, except that patients whose DFU overlies an area of treated osteomyelitis may be included, providing there exists a suitable base for application of the DermGEN.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Diabetes Type I
• Diabetes Type II
• Diabetic Foot
• Foot Ulcer

Intervention

Biological:
• DermGEN
DermGEN is a product created by a patented process that decellularizes and sterilizes donated human tissue.

Locations

Country	Name	City	State
Canada	Queen Elizabeth II Health Sciences Center	Halifax	Nova Scotia
Canada	St. Michael's Hospital	Toronto	Ontario

Sponsors (3)

Lead Sponsor	Collaborator
Dr. Paul F. Gratzer	Canadian Institutes of Health Research (CIHR), Nova Scotia Health Authority

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Wound Area Reduction Compared to Baseline	Digital photography was utilized to capture the appearance and size of the ulcer at each visit. In the photograph a measurement scale was shown beside the wound. The area of the wound was calculated by manually outlining wound edges on a digital image and then using the open source program ImageJ to calculate the area of the wound. For calculating the percentage change in area of the wound, the wound areas at each time point were divided by the size of the wound at baseline and multiplied by 100.	4 weeks
Secondary	Percentage of Patients With Complete Healing at Any Time Point	Complete healing is defined as 100% epithelialization without drainage. Digital photography was utilized to capture the appearance and size of the ulcer at each visit. In the photograph a measurement scale was shown beside the wound. The area of the wound was calculated by manually outlining wound edges on a digital image and then using the open source program ImageJ to calculate the area of the wound. For calculating the percentage change in area of the wound, the wound areas at each time point were divided by the size of the wound at baseline and multiplied by 100.	20 weeks
Secondary	Number of Patients With Adverse Events	Reporting the number of patients participating in the study having adverse events	20 weeks
Secondary	Number of Patients With Ulcer Reoccurrence in the Same Location After Complete Healing	Number of patients that reported a reoccurrence of the ulcer in the same location after complete healing at 1 year post treatment.	1 year
Secondary	Percent Change in Wound Size Compared to Baseline	Digital photography was utilized to capture the appearance and size of the ulcer at each visit. In the photograph a measurement scale was shown beside the wound. The area of the wound was calculated by manually outlining wound edges on a digital image and then using the open source program ImageJ to calculate the area of the wound. For calculating the percentage change in area of the wound, the wound areas at each time point were divided by the size of the wound at baseline and multiplied by 100. Note 100% equals complete closure of the wound.	20 weeks
Secondary	Percent Change in Wound Area From Baseline	change in area of wound in percent from initial presentation	12 Weeks